ethris – Enabling Therapies

Ethris develops innovative therapeutics based on proprietary platform technologies with high diversification potential that enable therapies for diseases with currently dissatisfying treatment options.




May 13, 2015
Ethris appoints Brad Guild, former Head of Emerging technologies at Pfizer, as Head of International Operations

Ethris GmbH, a pioneer in the emerging field of messenger RNA (mRNA) medicine, announces the appointment of Brad Guild as Head of International Operations. Mr Guild brings to Ethris more than 27 years of experience in developing nucleic acid therapies, gene therapies and antibodies, most recently as Head of Emerging Technology at Pfizer Worldwide in Cambridge, Mass.

March 25, 2015
Ethris moves to new facility

Since March 23, 2015, Ethris operates in a brand new building in Planegg. The new facility offers 1,500 square meters of lab and office space. Moving there has offered the opportunity to design the laboratories and offices specifically according to the needs of Ethris’ growing work force in R&D and administration.



ethris GmbH
Semmelweisstr. 3
82152 Planegg

T +49 89 89 55 788 0
F +49 89 89 55 788 18


Ethris explores the code of life for enabling patients’ bodies to make their own protein drugs. The proprietary SNIM®RNA platform and tailor-made delivery systems for systemic, local, oral and aerosol administration reduce gene therapy without genes to practice of medical need. SNIM®RNA “Transcript Therapies” are unprecedented treatment options for numerous diseases.